Stayble Therapeutics AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	6.9	13.03	24	24.95	12.14	Upgrade
Other Operating Expenses	0.08	-	-	-0	-0	Upgrade
Operating Expenses	6.97	13.18	24.1	24.95	12.14	Upgrade
Operating Income	-6.97	-13.18	-24.1	-24.95	-12.14	Upgrade
Interest Expense	-0.04	-0.05	-0.04	-0.03	-0.06	Upgrade
Interest & Investment Income	0.04	0.43	0.26	0.03	0.03	Upgrade
Currency Exchange Gain (Loss)	-	-	-	0.42	0.08	Upgrade
Other Non Operating Income (Expenses)	0.05	0.39	0.15	-	-	Upgrade
Pretax Income	-6.93	-12.42	-23.74	-24.53	-12.09	Upgrade
Net Income	-6.93	-12.42	-23.74	-24.53	-12.09	Upgrade
Net Income to Common	-6.93	-12.42	-23.74	-24.53	-12.09	Upgrade
Shares Outstanding (Basic)	59	38	26	14	14	Upgrade
Shares Outstanding (Diluted)	59	38	26	14	14	Upgrade
Shares Change (YoY)	55.90%	47.05%	86.06%	-	100.00%	Upgrade
EPS (Basic)	-0.12	-0.33	-0.92	-1.77	-0.87	Upgrade
EPS (Diluted)	-0.12	-0.33	-0.92	-1.77	-0.87	Upgrade
EBITDA	-	-13.03	-24	-	-	Upgrade
D&A For EBITDA	-	0.15	0.1	-	-	Upgrade
EBIT	-6.97	-13.18	-24.1	-24.95	-12.14	Upgrade
Revenue as Reported	0.05	0.39	0.15	0.29	0.01	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.